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Abstract
AIM
To assess liver fibrosis (LF) in hepatitis C virus (HCV) 
and alcoholic liver disease (ALD), estimate health 
outcomes and costs of new noninvasive testing strategies
METHODS
A Markov model was developed to simulate LF 
progression in HCV and ALD for a cohort of 40-year-
old men with abnormal levels of transaminases. Three 
different testing alternatives were studied: a single liver 
biopsy; annual Enhanced liver fibrosis (ELF™) followed 
by liver stiffness measurement (LSM) imaging as a 
confirmation test if the ELF test is positive; and annual 
ELF test without LSM. The analysis was performed 
from the perspective of a university hospital in Spain. 
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Clinical data were obtained from published literature. 
Costs were sourced from administrative databases of 
the hospital. Deterministic and probabilistic sensitivity 
analyses were performed.
RESULTS
In HCV patients, annual sequential ELF test/LSM and 
annual ELF test alone prevented respectively 12.9 
and 13.3 liver fibrosis-related deaths per 100 persons 
tested, compared to biopsy. The incremental cost-
effectiveness ratios (ICERs) were respectively €13400 
and €11500 per quality-adjusted life year (QALY). In 
ALD, fibrosis-related deaths decreased by 11.7 and 22.1 
per 100 persons tested respectively with sequential ELF 
test/LSM and annual ELF test alone. ICERs were €280 
and €190 per QALY, respectively.
CONCLUSION
The use of the ELF test with or without a confirmation 
LSM are cost-effective options compared to a single 
liver biopsy for testing liver fibrosis in HCV and ALD 
patients in Spain.
Key words: Cost-effectiveness analysis; Liver fibrosis; 
Noninvasive diagnostic assessment; Alcoholic liver 
disease; Hepatitis C
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Core tip: Noninvasive methods to diagnose liver fibrosis 
have been proposed as an alternative to liver biopsy 
in patients with abnormal level of transaminases. In 
a Markov model, sequential testing with enhanced 
liver fibrosis (ELF) test followed by liver stiffness 
measurement (LSM) significantly reduce liver-related 
lifetime morbidity and mortality, compared with biopsy, 
in hepatitis C virus (HCV) and alcoholic liver disease 
patients. Noninvasive methods are also associated with 
an increase in quality-adjusted life years and costs. 
Overall, they are cost-effective strategies compared 
with biopsy. ELF test with or without a confirmation 
LSM may represent a more affordable strategy than the 
“treat-all” option in HCV patients. 
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INTRODUCTION
The tremendous advances made in biomedicine and 
biotechnology during the last decade have led to 
long-standing “gold standard” invasive diagnostic 
and therapeutic procedures being challenged by 
novel, rapid, and noninvasive methods. Noninvasive 
diagnosis of liver fibrosis (LF) is one of the fields that 
has evolved most rapidly in recent years. Diagnosis 
and follow-up of liver diseases has long relied on liver 
biopsy, and only recently has its value as a method 
to assess the severity of LF or to follow-up disease 
progression been questioned[1]. Though biopsy is used 
to stage most cases of liver disease, it is well known 
that this procedure has several limitations. First, liver 
biopsies sample only an extremely small portion of 
the liver (1/50000) and, therefore, sampling errors 
can occur, especially when smaller sized biopsies are 
analyzed[2]. In addition, histological examination is 
prone to intra- and interobserver variation, which may 
occur even when widely validated systems are used to 
score liver damage. Finally, liver biopsy is an invasive 
procedure with associated morbidity: pain occurs in 
20% of patients and major complications (such as 
bleeding or hemobilia) in 0.5%[3]. For this reason, liver 
biopsy has poor tolerance, particularly if it needs to be 
repeated over time in an individual patient. Moreover, 
patients are nowadays aware of noninvasive methods 
to assess the degree of liver damage and so they may 
be reluctant to undergo an invasive procedure. 
Most well-validated noninvasive methods have 
shown good diagnostic accuracy in identifying patients 
with a significant degree of fibrosis (i.e., fibrosis 
expanding beyond the portal tract)[4]. Sensitivity and 
specificity above 85% can be considered sufficient 
due to the lack of relevant clinical consequences for 
false-positive and false-negative cases. In addition, 
noninvasive tests can be repeated over time, and in 
cases of indeterminate results two or more methods 
can be combined. Although the identification of 
significant fibrosis (≥ F2) has been regarded as 
an important target [particularly in the field of viral 
hepatitis, hepatitis C virus (HCV)], its real value as 
a static measure of disease severity is arguable. The 
identification of individuals with bridging fibrosis or liver 
cirrhosis is more critical: in such cases, sensitivity must 
be very high, not only due to the potential indication 
of a specific treatment, but also because screening 
for hepatocellular carcinoma and gastroesophageal 
varices is mandatory in patients with liver cirrhosis. 
Fortunately, the performance of noninvasive methods 
to assess the presence of cirrhosis is excellent[4,5].
A different approach is the sequential evaluation of 
the severity of liver disease when screening candidates 
for a specific treatment or intervention or a different 
follow-up, i.e., prioritization in the treatment of HCV, 
interventions in alcohol consumption or diet, and 
follow-up of patients with cirrhosis. The sequential use 
of an enhanced liver fibrosis (ELF) test (as a blood test 
for patients with suspected liver disease), and LSM (as 
a specific tool to confirm the presence and severity of 
liver disease) has been proposed[6] and, theoretically, it 
could be easy to apply. However, health and economic 
implications of this approach have not been reported. 
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Therefore, the aim of the current study is to assess 
both the accuracy of the sequential use of ELF test/
LSM in the evaluation of the severity of liver disease 
and its cost-effectiveness compared with the use of 
biopsy in patients with HCV or alcoholic liver disease 
(ALD). 
MATERIALS AND METHODS
Model overview
A Markov model was developed to estimate clinical 
outcomes and associated costs of the different options 
for assessing liver fibrosis. Three mutually exclusive 
testing strategies were considered in the analysis (Table 
1): (1) a unique percutaneous liver biopsy; (2) annual 
ELF test with confirmation LSM in case of a positive 
ELF score; and (3) annual ELF test alone. Outcomes 
were also computed assuming that no test for liver 
fibrosis was performed.
In the base case analysis patients were 40-year-
old men with abnormal levels of transaminases 
and diagnosed with HCV or ALD. The analysis was 
conducted separately for each etiology group. In the 
Markov model, disease progression is represented as 
transitions between different health states over time, 
which was modeled here as a series of 3-mo cycles 
(Figure 1A and B). Individuals face probabilities of 
moving to a different state according to their initial and 
ensuing health condition, treatment, and age. Each 
health state is associated with specific utility levels 
and costs (e.g., hospitalization, screening, or follow-
up). Clinical outcomes considered in the analysis 
were the rate of correct diagnosis of each test (true 
positives and true negatives), frequency of adverse 
health events, and quality-adjusted life years (QALYs)[7]. 
Direct healthcare costs of each testing strategy were 
estimated from the perspective of a health care provider 
(Hospital Clínic Barcelona). Differences in QALYs and 
costs between testing strategies were used to compute 
incremental cost-effectiveness ratios (ICERs)[8]. QALYs 
and costs were evaluated from the beginning of the 
liver assessment with a lifetime horizon and were 
discounted at an annual rate of 3% in accordance 
with common practice in the literature and Catalan 
Health Service (CatSalut) guidelines[9-11]. The analysis 
was performed using STATA 13.1 (StataCorp, College 
Station, Texas, United States).
Markov model for HCV
The structure of the Markov model used in the analysis 
is similar to earlier work done for surveillance and 
treatment of HCV (Figure 1A)[12-15]. The model is a 
simplified representation of the natural history of HCV. 
Fibrosis severity is characterized by three different 
health states according to the METAVIR scoring 
system: no fibrosis or mild fibrosis (F0-F1); moderate 
or severe fibrosis (F2-F3); and compensated cirrhosis 
(F4). An individual with compensated cirrhosis may 
develop complications and move to a decompensated 
cirrhosis (DC) state. Both compensated and de-
compensated cirrhosis may lead to hepatocellular 
carcinoma (HCC). Individuals with DC or HCC are 
candidates for liver transplantation (LTX), which takes 
them to a post-LTX state or death. The additional 
following assumptions were made in the present 
model: (1) fibrosis caused by HCV is not reversible but 
once SVR has been achieved, progression of fibrosis 
is permanently stopped[16]; (2) responders to antiviral 
treatment achieve SVR in the quarter following the 
end of the treatment; (3) the efficacy of antiviral 
treatment is the mean efficacy in untreated genotype 
1 as reported by Afdhal et al[17] (ION-1 Study); and 
(4) there is no excess mortality associated with LF 
(including compensated cirrhosis), as the main cause 
of death of these individuals is accounted for in the 
model by the other health states (HCC, DC, LTX, and 
post-LTX states).
In the model HCV individuals that test positive 
for LF ≥ 2 receive a combination of sofosbuvir and 
ledipasvir over a 12-wk period. Recent research has 
shown that the combination of these drugs achieves 
high levels of sustained virological response (SVR) 
in both treatment-naïve and treatment-experienced 
HCV genotype 1 patients[17-19]. Additional evidence 
shows that the combination of these two drugs is cost-
effective compared with standard of care for most 
eligible patients in the United States[20]. We assumed 
that only individuals that test positive for LF are 
treated with antivirals. Patients in a DC, HCC, LTX, and 
post-LTX state received the standard of care.
Markov model for ALD
The model used for ALD (Figure 1B) is based on earlier 
work on fibrosis progression in heavy drinkers[21-24]. 
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Table 1  Test strategies
Strategy First test result Confirmation test result
Negative Positive Negative Positive
Single biopsy No action Treatment + annual screening for HCC and 
DC if F = 4
No confirmation test is performed
Annual ELF/LSM Annual ELF LSM Annual ELF Treatment + annual screening for HCC and 
DC if F = 4
Annual ELF Annual ELF Treatment + annual screening for HCC and 
DC if F = 4
No confirmation test is performed
ELF: Enhanced liver fibrosis test; LSM: Liver stiffness measurement; HCC: Hepatocellular carcinoma; DC: Decompensated cirrhosis.
Soto M et al . Cost-effectiveness of ELF to assess liver fibrosis in HCV and ALD
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state; and (4) drinkers in a LF state face an elevated 
mortality risk, as they are confronted with causes 
of death different from those directly linked to liver 
disease (e.g., accidents).
Detoxification for ALD individuals with positive 
LF results consists of psychological and psychiatric 
therapy provided by Hospital Clínic staff for 1 year. The 
model assumed that the length of treatment did not 
depend on the drinking behavior of individuals; that 
is, both abstainers and individuals with early relapse 
ALD individuals are annually tested for LF and those 
obtaining an F ≥ 2 result receive detoxification 
therapy. In the quarter following the beginning of 
therapy, some ALD individuals achieve abstinence. 
Other assumptions specific to the ALD model are: (1) 
all patients receiving a positive diagnosis of LF agree 
to undergo detoxification therapy; (2) individuals in an 
abstinence state may relapse and return to a “drinker” 
state; (3) fibrosis in its medium/severe (F2-F3) 
degree is reversible if individuals are in an abstinence 
Mild or no
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sustained
virological
response
Mild or no
fibrosis and 
abstinence
Mild or no
fibrosis and 
drinking
Moderate
fibrosis and 
drinking
Moderate
fibrosis and 
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Death
(from any state)
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Figure 1  Markov models for hepatitis C virus (A) and alcoholic liver disease (B).
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received a full year therapy.
Model parameters and data sources
Model parameters are listed in Table 2. Estimates 
for clinical values (i.e., transition probabilities, test 
accuracy, effectiveness of antivirals, alcohol abstinence 
and relapse rates, and utilities) were obtained from 
a literature search in Medline[12,15,17,22-36]. Priority was 
given to estimates for Spanish population or to studies 
based on a large number of patients. Whenever it 
was possible, sensitivity and specificity estimates 
were specific to each etiology group. In ALD patients, 
for whom no specific information on ELF testing was 
available, it was assumed that the ELF test had the 
same accuracy as in HCV individuals[26]. All specificity 
and sensitivity parameters were changed in the 
sensitivity analysis to explore how these assumptions 
affected baseline results. In the base case analysis, 
liver biopsy was assumed to have a 90% sensitivity 
and specificity for both groups of individuals[25]. 
Research has shown that biopsy may underdiagnose 
cirrhosis in up to 14.5% of HVC individuals[37], and 
such lower accuracy levels were considered in the 
sensitivity analysis as well.
In the absence of utility estimates for the Spanish 
population, we used standardized measures of health 
status for HCV individuals as reported by Wright 
et al[27] (Supplementary Table S1). These values 
are in accordance with data commonly used in the 
literature[12]. Cost data were obtained from Hospital 
Clínic sources, published literature[14], and the Spanish 
Ministry of Health & Social Services and public 
sources[38,39] (Supplementary Table S2). Historical costs 
were adjusted to 2013 prices according to the Spanish 
price index for hospital services.
Percutaneous biopsy has a mortality risk of about 
9 of every 10000 persons tested[28], which was 
accounted for in the model. Biopsy is also subject to 
discomfort and nonfatal adverse events. Although 
there are no direct measures of the effects of biopsy 
on utility, recent research assumed that nonfatal 
adverse events are associated with an annual utility 
decline of 0.2[15,28]. Because this assumption disfavors 
biopsy, sensitivity analyses were performed to assess 
the consequences on the results if a smaller reduction 
in utility is assumed.
Wright et al[27] report a mean utility decrement 
of 0.11 during treatment with HCV antivirals and a 
utility rise of 0.05 in individuals for whom treatment 
is successful. Following the findings of the authors, 
we assumed a 0.11 utility drop during one quarter for 
individuals that are treated and a permanent increase 
of 0.05 for individuals that achieve an SVR state. 
Utilities for ALD individuals were assumed identical 
to those used in HCV. Sensitivity analyses were 
undertaken to explore the robustness of results with 
changes in these assumptions.
No reliable epidemiological data for prevalence 
of LF and cirrhosis in HCV and ALD for the Spanish 
population were available. Following clinical opinion and 
earlier work[15] for the United Kingdom, we assumed a 
base case prevalence of F ≥ 2 of 53% among the HCV 
and ALD population. The corresponding prevalence 
for compensated cirrhosis was 20%. Prevalence rates 
were varied in the sensitivity analyses to explore the 
robustness of base case results.
Sensitivity analysis
One-way deterministic sensitivity analysis was 
performed to explore the parameters that had the 
highest impact on QALYs and costs. Low- and high-
value parameters used for the analysis are described 
in Table 2. The general rule for selection of extreme 
values was to use the confidence interval bounds 
reported in the cited literature. In some cases, such as 
the probability of liver transplantation, extreme values 
corresponded to the minimum and maximum values 
used in the literature on cost-effectiveness analysis for 
the treatment of HCV[12]. The analysis only compared 
results between biopsy and the sequential ELF test/
LSM. Results are presented in the form of tornado 
diagrams (Figures 2 and 3).
Probabilistic sensitivity analysis was performed by 
running 10000 Monte Carlo simulations per etiology 
group. New parameter values were randomly drawn 
from probability density functions in each iteration.
RESULTS
Base case results: HCV
Table 3 summarizes the results for HCV. Biopsy and 
ELF test alone had the highest rate of true F ≥ 2 
cases detected (47.7%), and sequential ELF test/LSM 
produced the largest rate of true negatives (44.5%). 
In cirrhotic HCV patients, biopsy and ELF test yielded 
the highest rate of true positives detected (18.1%), 
and biopsy had the highest rate of true negatives 
(71.9%).
All testing options resulted in a substantial 
reduction in the number of events compared with the 
no-testing option. In particular, sequential ELF test/
LSM and ELF test alone reduced the frequency of new 
cases of cirrhosis to 0.9% and 0.2%, respectively. 
Similarly, liver fibrosis-related death was 47.9%, 
13.5%, 0.6%, and 0.2% under the no-testing, biopsy, 
sequential ELF test/LSM, and ELF test alone options, 
respectively.
ELF test alone was the most effective strategy 
(16.75 QALYs) and it had the highest associated cost 
(€60443 per patient). The ICERs for ELF test/LSM and 
ELF test alone were €13438 and €11484 per QALY, 
respectively.
Base case results: ALD
Results for ALD patients are presented in Table 4. As 
in the HCV case, biopsy and ELF test alone produced 
Soto M et al . Cost-effectiveness of ELF to assess liver fibrosis in HCV and ALD
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Table 2  Transition probabilities, accuracy of tests, and other parameters
Baseline Range PSA distribution1 Source
Annual transition probabilities in HCV (%)
From To
   F0-F1 F2-F3      2.5   2.0-3.1 β  (2.5; 0.4) [27]
   F2-F3 F4      3.7   2.5-5.3 β  (3.7; 0.7) [27]
   F4 DC      3.9   3.1-5.0 β  (3.9; 0.5) [29]
   F4 HCC      3.7   3.2-4.2   β  (3.7; 0.25) [30]
   DC HCC      6.8   - - [31]
   DC/HCC LTX   2     1-21 U (1; 21) [12,32]
   DC Death    12.7   - - [31]
   HCC Death 43   - - [29]
   LTX Death 19   18-20 - [33]
   Post-LTX Death      4.6   - - [33]
Response rate to treatment in HCV (%)
   F0-F3  100.0  98.0-100 β  (99.4; 0.6) [17]
   F4    97.0   84.2-99.9 β  (97.0; 2.9) [17]
Annual transition probabilities in ALD (%)
From To
   F0-F1 F2-F3      2.0   1.1-3.2 β  (2; 0.5) [22]
   F0-F1 (abstainers) F2-F3        0.01   - - [22]
   F2-F3 F4 20     7-33 U (7; 33) [22]
   F2-F3 (abstainers) F0-F1 26   10-50 U (10; 50) [34]
   F4 DC 23   18-29 β  (23; 2.75) [23]
   F4 HCC      1.7   1.2-2.2  β  (1.7; 0.25) [30]
   DC HCC        2.15   - - [24]
   DC/HCC LTX   2     1-21 U (1; 21) [12,32]
   DC Death    17.5   16-19 β  (17.5; 0.75) [24]
   HCC Death 43   - - Assumed as for HCV
   LTX Death 19   18-20 - [33]
   Post-LTX Death      4.6   - - [33]
Abstinence rate following therapy (%)
   If diagnosed F2-F3 27   14-43 β  (27; 7) [35]
   If diagnosed F4 66   46-82 β  (66; 9) [35]
Probability of relapse before 12 mo (%)
   F2-F3 45   17-77 β  (45; 15) [35]
   F4 58   33-88 β  (58; 14) [35]
Test accuracy for F ≥ 2 (%)
   ELF Sensitivity 90   85-93 β  (90; 1.9) [26]
   ELF Specificity 52   43-61 β  (52; 4.6) [26]
   LSM Sensitivity (HCV) 79   75-83 β  (79; 2.0) [15]
   LSM Specificity (HCV) 89   84-93 β  (89; 2.0) [15]
   LSM Sensitivity (ALD) 81   70-88 β  (81; 4.5) [15]
   LSM Specificity (ALD) 92   76-98 β  (92; 5.5) [15]
   Biopsy Sensitivity 90   85-95 U (85; 95) Based on [25]
   Biopsy Specificity 90   85-95 U (85; 95) Based on [25]
Test accuracy for F = 4 (%)
   ELF Sensitivity 90   84-94 - [26]
   ELF Specificity 53   46-59 - [26]
   LSM Sensitivity (HCV) 84   72-91 - [15]
   LSM Specificity (HCV) 77   50-92 - [15]
   LSM Sensitivity (ALD) 86   76-92 - [15]
   LSM Specificity (ALD) 83   74-89 - [15]
   Biopsy Sensitivity 90   85-95 U (85; 95) Based on [25]
   Biopsy Specificity 90   85-95 U (85; 95) Based on [25]
Other Parameters
   Relative risk of mortality for drinkers      2.0   1.0-4.0 U (1.0; 4.0) Assumption
   Relative risk of DC for F4 abstainers        0.33 0.33-1.0   U (0.33; 1.0) Based on [36]
   Relative risk of HCC for F4 abstainers        0.33 0.33-1.0   U (0.33; 1.0) Based on [36]
   Cohort’s initial age (years) 40   30-50 γ  (40; 10) Assumption
   Prevalence of LF (F ≥ 2) (%) 53   40-66 U (40; 66) Assumption
   Prevalence of cirrhosis (F = 4) (%) 20   14-27 U (14; 27) Assumption
   Death probability related to biopsy (%)        0.09   0.06-0.12 β  (0.09; 0.01) [28]
   Prob. of nonfatal adverse event related to 
   Biopsy (%)
       0.72   - - [28]
1PSA: Probabilistic sensitivity analysis; In beta (β ) and gamma (γ ) distributions, parameters correspond to mean and SD; In uniform (U) distributions, 
parameters correspond to minimum and maximum values. F0-F1: No fibrosis or mild fibrosis; F2-F3: Moderate or severe fibrosis; F4: Cirrhosis. ELF: 
Enhanced liver fibrosis test; LSM: Liver stiffness measurement; LF: Liver fibrosis; DC: Decompensated cirrhosis; HCC: Hepatocellular carcinoma; LTX: 
Liver transplantation.
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the highest rate of true F ≥ 2 detected (47.7%), while 
ELF test/LSM had the highest rate of true negatives 
(45.2%). In cirrhotic ALD patients, biopsy and ELF test 
delivered the highest rate of true positives (18.1%), 
while ELF test/LSM generated the highest rate of true 
negatives (73.5%). 
ELF test/LSM or ELF test alone reduced the fre-
quency of events significantly although frequency 
rates remained high. Liver fibrosis-related death was 
68.8%, 66.5%, 54.8%, and 44.4% under the no-
testing, biopsy, sequential ELF test/LSM, and ELF test 
alone options, respectively.
In this type of patients, ELF testing alone produced 
the largest number of QALYs (11.94) but it was the 
most costly option (€14661 per patient). The ICERs of 
sequential ELF test/LSM and ELF test alone are €280 
and €189 per QALY, respectively.
Deterministic sensitivity analysis
Results of the deterministic analysis for key parameters 
in HCV individuals are summarized in Figure 2. The 
ICER was mostly sensitive to variations in the discount 
Discount rate
Cost of antivirals
Initial age
Prob. of progression to F4
Biopsy sensitivity for F ≥ 2
Prob. of progression from F4 to HCC
LSM specificity for F ≥ 2
Cost of ELF test
Cost of biopsy
Utility decrement of biopsy
ELF specificity for F ≥ 2
LSM sensitivity for F ≥ 2
ELF sensitivity for F ≥ 2
SVR rate (no cirrhosis)
Prevalence of F ≥ 2
Biopsy specificity for F ≥ 2
SVR rate (cirrhosis)
Incremental cost-effectiveness ratio (HCV)
5000    7500   10000  12500   15000   17500  20000   22500   25000
€ per QALY
Parameter values
              High
              Low
              Base case
Figure 2  Deterministic sensitivity analysis for hepatitis C virus. HCV: Hepatitis C virus; QALY: Quality-adjusted life year; ELF: Enhanced liver fibrosis test; LSM: 
Liver stiffness measurement; HCC: Hepatocellular carcinoma.
Cost of detoxification therapy
Prob. of alcohol relapse (F2/F3)
Prob. of abstinence if diagnosed F2/F3
Cost of ELF test
Prob. of abstinence if diagnosed F4
Prevalence of F ≥ 2
Discount rate
Cost of LSM test
Initial age
Prob. of progression to F2 (drinkers)
Cost of biopsy
LSM sensitivity for F ≥ 2
Prob. of progression to F4 (drinkers)
ELF sensitivity for F ≥ 2
Biopsy sensitivity for F ≥ 2
Biopsy specificity for F ≥ 2
Incremental cost-effectiveness ratio (ALD)
-1000  -750  -500   -250     0     250   500    750  1000  1250  1500
€ per QALY
Parameter values
            High
            Low
            Base case
ELF + LSM 
dominant
ELF + LSM dominant
ELF + LSM dominant
Figure 3  Deterministic sensitivity analysis for alcoholic liver disease. ALD: Alcoholic liver disease; QALY: Quality-adjusted life year; ELF: Enhanced liver fibrosis 
test; LSM: Liver stiffness measurement.
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rate, cost of antivirals, and the cohort’s initial age. The 
lowest ICER (€5800 per QALY) was obtained when 
the discount rate was 0, whereas the highest ICER 
(€21400 per QALY) occurred when the assumed cost 
of antivirals was high (€72000 for a 12-wk treatment). 
The remaining parameters of the model had a minor 
impact.
Deterministic sensitivity results for ALD are shown 
in Figure 3. Sequential ELF test/LSM was superior to 
biopsy when the assumed cost of detoxification therapy 
was low (€173 per individual treated). ELF test/LSM 
was also superior to biopsy when individuals diagnosed 
Table 3  Diagnostic accuracy, health outcomes and costs in hepatitis C virus patients
Diagnostic accuracy (%)1 Biopsy ELF/LSM ELF
Liver fibrosis (F ≥ 2)
   TP 47.7 37.7 47.7
   FN   5.3 15.3   5.3
   TN 42.3 44.5 24.4
   FP   4.7   2.5 22.6
Cirrhosis (F4)
   TP 18.1 15.2 18.1
   FN   2.0   4.9   2.0
   TN 71.9 71.2 42.3
   FP   8.0   8.6 37.5
Frequency of events (%) No testing Single Annual Annual
Biopsy ELF/LSM ELF
Compensated cirrhosis (new cases) 40.4 16.8   0.9   0.2
Decompensated cirrhosis 24.7   7.0   0.3   0.1
Hepatocellular carcinoma 25.6   7.2   0.3   0.1
Fibrosis-related death 47.9 13.5   0.6   0.2
QALYs, costs and ICER No testing Single Annual Annual
Biopsy ELF/LSM ELF
QALYs   12.36   15.27   16.33   16.75
Cost per patient (€) 24 353 43 447 57 691 60 443
ICER relative to “no testing” 6 561 8 397 8 221
ICER relative to biopsy 13 438 11 484
1Percentage of cases detected on first test. Initial prevalence: liver fibrosis = 53%; cirrhosis = 20%. TP: True positives; FN: False negatives; TN: True 
negatives; FP: False positives; QALY: Quality-adjusted life year; ICER: Incremental cost-effectiveness ratio (€ per QALY); ELF: Enhanced liver fibrosis test; 
LSM: Liver stiffness measurement.
Table 4  Diagnostic accuracy, health outcomes and costs in alcoholic liver disease patients
Diagnostic accuracy (%)1 Biopsy ELF/LSM ELF
Liver fibrosis (F ≥ 2)
TP 47.7 38.6 47.7
FN   5.3 14.4   5.3
TN 42.3 45.2 24.4
FP   4.7   1.8 22.6
Cirrhosis (F4)
TP 18.1 15.6 18.1
FN   2.0   4.5   2.0
TN 71.9 73.5 42.3
FP   8.0   6.4 37.5
Frequency of events (%) No testing Single Annual Annual
Biopsy ELF/LSM ELF
Compensated cirrhosis (new cases) 51.8 49.7 39.0 27.8
Decompensated cirrhosis 64.7 61.4 38.7 30.2
Hepatocellular carcinoma 10.2   9.8   7.3   5.8
Fibrosis-related death 68.8 66.5 54.8 44.4
QALYs, costs and ICER No testing Single Annual Annual
Biopsy ELF/LSM ELF
QALYs   9.2     9.55   10.88   11.94
Cost per patient (€) 13 985 14 209 14 581 14 661
ICER relative to “no testing” 640 355 247
ICER relative to biopsy 280 189
1Percentage of cases detected on first test. Initial prevalence: liver fibrosis = 53%; cirrhosis = 20%. TP: True positives, FN: False negatives; TN: True 
negatives; FP: False positives; QALY: Quality-adjusted life year; ICER: Incremental cost-effectiveness ratio (€ per QALY); ELF: Enhanced liver fibrosis test; 
LSM: Liver stiffness measurement. 
Soto M et al . Cost-effectiveness of ELF to assess liver fibrosis in HCV and ALD
3171 May 7, 2017|Volume 23|Issue 17|WJG|www.wjgnet.com
as F2/F3 had a high probability of abstinence (43%) 
and a low probability of relapse (17%) within a year. 
In all other cases studied, the ICER of ELF test/LSM 
compared to biopsy was smaller than €1400 per QALY.
Probabilistic sensitivity analysis results
Figure 4 presents cost-effectiveness acceptability 
curves[40] for HCV and ALD. The figure shows the 
probability that sequential ELF test/LSM is cost-
effective compared to biopsy at different levels of 
willingness-to-pay (WTP) for one QALY. At a WTP of 
€30000 per QALY the probability that ELF test/LSM is 
cost-effective is 90.1% and > 99.9% in HCV and ALD, 
respectively. For this last etiology group, ELF test/LSM 
is cost-effective with a probability larger than 85% at 
any WTP.
DISCUSSION
To our knowledge, this is the first study that estimates 
the cost-effectiveness of the sequential use of ELF 
test/LSM for the assessment of liver fibrosis. Our 
findings show that ELF test/LSM is a cost-effective 
strategy for a WTP of €30000 per QALY, the cost-
effectiveness threshold commonly used in Spain[41]. 
At this threshold, the net health benefit[42] of ELF test/
LSM compared to biopsy is €17526 and €39450 per 
HCV and ALD patient, respectively. The probabilistic 
sensitivity analysis showed that the results were 
robust.
Previous research for HCV patients in the UK 
showed that treatment with antiviral agents without 
liver testing was the most cost-effective strategy to 
reduce liver fibrosis occurrence and progression[15]. 
However, that study was based on interferon-
containing options. New, interferon-free options 
are costly and providing all HCV patients with the 
treatment can be a financially unsustainable strategy 
for some countries. In this situation, an ELF test/LSM 
strategy may help to balance sustainability with right 
care since it would be able to promptly identify non-
invasively those HCV patients in early stages of liver 
fibrosis and to grant them access to treatment.
In ALD patients, sequential ELF test/LSM and ELF 
test alone are both cost-effective strategies compared 
with biopsy. Moreover, for this group of patients ELF 
testing alone is only slightly more expensive than the 
ELF test/LSM strategy. Therefore, ELF testing alone is 
a highly cost-effective strategy for ALD patients. 
Finally, because ELF can be easily performed at 
primary health care centers it can provide a more 
equitable access to early diagnostic and treatment 
for HVC and ALD patients with incipient liver fibrosis. 
Moreover, the sequential use of ELF test/LSM may 
contribute to a better selection of patients in need of 
treatment, thus improving on care appropriateness 
and potentially reducing costs for both patients and 
hospitals. 
The study has several limitations. First, nume-
rous parameters were sourced from small or single 
studies. This was especially apparent for information 
regarding ELF test accuracy and the efficacy of 
detoxification therapy and alcohol relapse rates, 
among others. Further research is needed to address 
this shortcoming. Additionally, most of the clinical 
data and prevalence rates used in the analysis came 
from studies carried out outside of Spain. Although 
discrepancies in clinical data across countries may 
affect country-specific effectiveness and, therefore, 
cost-effectiveness ratios, we do not expect important 
differences in patient characteristics and professional 
expertise in our country compared to others. Moreover, 
the sensitivity analysis showed that results were robust 
to wide variations in the underlying clinical parameters. 
Secondly, the estimates for sensitivity (90%) and 
specificity (90%) of liver biopsy were obtained from 
a study whose estimates are themselves based on 
clinician opinion[25]. Nevertheless, the sensitivity 
analysis showed that variations in the accuracy of 
biopsy did not affect the main results. Finally, cost 
estimates were obtained from our hospital or from 
Spanish sources. Differences in economic data across 
countries may affect the final results. However, the 
wide variation in the unit costs that we have used in 
the sensitivity analysis systematically corroborated 
that the sequential ELF test/LSM strategy was cost-
effective.
In conclusion, testing for liver fibrosis annually with 
sequential ELF test/LSM or ELF test alone resulted in a 
substantial reduction in the number of events (cirrhosis, 
hepatocellular carcinoma, and fibrosis-related death) 
and a significant increase in QALYs for HCV and ALD 
patients, compared with a single liver biopsy. Out of 
the three options analyzed, ELF testing alone had the 
best health outcomes for both etiology groups (i.e., 
HCV and ALD), but it was also the most costly of the 
strategies. In light of these results, sequential ELF 
test/LSM can be considered as an option providing a 
balance between proper care and costs, especially in 
HCV patients. In ALD, the preferred strategy is ELF 
testing alone as its low incremental cost and large 
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Figure 4  Cost-effectiveness acceptability curves in hepatitis C virus and 
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associated health gains make it a highly cost-effective 
option.
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Background
The tremendous advances made in biomedicine and biotechnology during 
the last decade have led to long-standing “gold standard” invasive diagnostic 
and therapeutic procedures being challenged by novel, rapid, and noninvasive 
methods. Noninvasive diagnosis of liver fibrosis (LF) is one of the fields that has 
evolved most rapidly in recent years. Diagnosis and follow-up of liver diseases 
has long relied on liver biopsy, and only recently has its value as a method to 
assess the severity of LF or to follow-up disease progression been questioned. 
Though biopsy is used to stage most cases of liver disease, it is well known that 
this procedure has several limitations.
Research frontiers
The aim of the current study is to assess both the accuracy of the sequential 
use of enhanced liver fibrosis (ELF) test/liver stiffness measurement (LSM) 
in the evaluation of the severity of liver disease and its cost-effectiveness 
compared with the use of biopsy in patients with hepatitis C virus (HCV) or 
alcoholic liver disease (ALD). 
Innovations and breakthroughs
In HCV patients, annual sequential ELF test/LSM and annual ELF test alone 
prevented respectively 12.9 and 13.3 liver fibrosis-related deaths per 100 
persons tested, compared to biopsy. The incremental cost-effectiveness ratios 
(ICERs) were respectively €13400 and €11500 per quality-adjusted life year 
(QALY). In ALD, fibrosis-related deaths decreased by 11.7 and 22.1 per 100 
persons tested respectively with sequential ELF test/LSM and annual ELF test 
alone. ICERs were €280 and €190 per QALY, respectively.
Applications
The authors found that the use of the ELF test with or without a confirmation 
LSM are cost-effective options compared to a single liver biopsy for testing liver 
fibrosis in HCV and ALD patients in Spain.
Peer-review
This is a very clearly written paper, and the authors make a good case for 
why the topic is an important one, particularly in a medical landscape that is 
changing rapidly as new technologies become available.
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